Gland pharma sees volatility in the grey market premium ahead of its listing. Will it be a Hit or a miss?
Gland Pharma has robust business model and strong financial performance since 2017 when Fosun took over major stake; post IPO its stake would come down to 58%. The IPO is worth investing if the geopolitical tension remains subdued. However investors wary of external risk may consider investing based on their risk appetite.